Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
684 Leser
Artikel bewerten:
(2)

Cigna International survey finds perception of safety and acceptance of COVID-19 vaccines improving

Finanznachrichten News

Key research findings:

  • Vaccine rollout progressing well - 25% of our sample of over 13,000 people are now vaccinated
  • Overall vaccine acceptance up from 63% to 66%, and 60% of people believe vaccines will be readily available to them, up 2%
  • Notable differences between markets, particularly in markets where vaccination rates are lower
  • Significant numbers continue to be concerned about COVID-19 vaccines
  • Social media not a trusted source - only 5% of people trust social as their best source of information on COVID-19 vaccines

HONG KONG, June 2, 2021 /PRNewswire/ -- Cigna's (NYSE:CI) International Markets business today published the second edition of its COVID-19 Vaccine Perception Study which shows that overall rates of vaccines acceptance have increased from 63% to 66% in a single month. The study, which aims to highlight perceptions and attitudes towards COVID-19 vaccines around the world, surveyed over 13,000 people across 11 markets.

Cigna Logo

Vaccine acceptance and perception of safety are improving

Improvements in vaccine acceptance were seen in China, Singapore, Thailand and Spain. The ongoing successful rollout of vaccines means that overall, 6 out of 10 of our respondents now believe the vaccine will be available to them, a month on month increase of 2%. This is good news for governments and health authorities as it reflects improving confidence in their vaccine rollout programs.

This month's data also shows that 55% of respondents now believe COVID-19 vaccines are safe. This is driven in part by the increased number of people who have already been vaccinated, across the 11 markets we have studied, 1 in 4 people who we surveyed have now received at least one shot.

Commenting on the report, Jason Sadler, President, Cigna International Markets said: "With global vaccine rollout progressing well, the report indicates that there is much to be positive about. Social acceptance plays an important role in trust, so being vaccinated, or knowing someone who has been vaccinated, leads to more positive views of the vaccine. 83% of those vaccinated trust COVID-19 vaccines are safe, whereas only 46% of those unvaccinated feel the same. Challenges remain, but the improved perception around vaccines and their safety should be welcomed."

Several markets still face issues regarding perceptions of vaccine safety. The difference between markets is striking. In South Korea for example, just 32% of respondents agreed the COVID-19 vaccines available are 'very safe', this compared to 80% in the UK and 78% in the UAE. The other markets where concerns about the safety of COVID-19 vaccines remain high include Taiwan, Thailand and Hong Kong, all of which had less than 40% of respondents agreeing they are safe.

To communicate the facts about safety effectively and encourage vaccine uptake, it is critical the authorities in these markets target their public information campaigns through the most trusted channels in their respective markets to have the greatest impact.

Our research busts some of the myths - social media is not a trusted source.

Throughout the pandemic, misinformation on social media has created obstacles to the successful handling of the pandemic and the vaccine rollout. However, Cigna's COVID-19 Vaccine Perception Study shows that only 5% of the respondents consider social media to be the most trusted source of information, despite the vast majority being social media users.

Social media falls behind government bodies, family doctors, private healthcare providers and TV news and documentaries. Although in the 18-34 age bracket social media is the fourth most trusted source, for the over 35s it falls to the seventh most trusted source. There is a marked difference between generations on this, with 7% of 18-34-year-old saying it is their most trusted source, while in the over 55s this number falls to just 2%.

Commenting on the research Dr Daniel Ober, Medical Officer, Cigna International Markets Americas said: "Our research shows people increasingly understand and trust COVID-19 vaccines. We know that vaccination is a critical part of ending this pandemic. The science demonstrates the overwhelming effectiveness of vaccines to prevent severe COVID-19 infections, hospitalizations and even death. Getting vaccinated is the most important thing for us to do, not just for ourselves, but for those we love. Our advice is clear, get vaccinated as soon as you can!"

Download the report

Click here to download the full COVID-19 Vaccine Perception Study Report - 2nd edition

Click here to download the COVID-19 Vaccine Perception Study Report - 1st edition

Research methodology:

Cigna partnered with You Gov, the international research data and analytics group, engaged with 13,387 respondents between 16th and 20th April 2021. The respondents were a representative sample aged 18 or over, 52% male and 48% female, from across 11 markets: Mainland China, Hong Kong, New Zealand, Singapore, South Korea, Spain, Taiwan, Thailand, UAE, UK and US.

About Cigna

Cigna Corporation is a global health service company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna Life Insurance Company of New York, Connecticut General Life Insurance Company, Express Scripts companies or their affiliates, and Life Insurance Company of North America. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products including group life, accident and disability insurance. Cigna maintains sales capability in over 30 countries and jurisdictions, and has more than 170 million customer relationships throughout the world. To learn more about Cigna, including links to follow us on Facebook or Twitter, visit www.cigna.com.

Logo - https://mma.prnewswire.com/media/1246896/image_5010983_22394327_Logo.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.